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Abstract 
Introduction. Unnoticed and untreated depression is prevalent among patients with chronic 
respiratory insufficiency. Comorbid depression causes suffering and worsens patients’ outcomes. 
Objectives. The objective of this evaluation was to assess preliminary outcomes of a depression 
screening protocol among chronic respiratory insufficiency patients at a tertiary care pulmonary 
outpatient clinic. 
Methods. In the depression screening protocol, the patients filled the Depression Scale (DEPS) 
questionnaire. Patients whose scores suggested depression were offered the opportunity of a 
further evaluation of mood at a psychiatric outpatient clinic. The outcomes of the protocol were 
evaluated retrospectively from the patient records. 
Results. During the period of evaluation, 238 patients visited the outpatient clinic. DEPS was 
administered to 176 patients (74%), of whom 60 (34%) scored ≥9 (out of 30), thus exceeding the 
cut-off for referral. However, only 13 patients were referred, as the remainder declined the 
referral. Finally, seven patients were evaluated at the psychiatric clinic, and they all were deemed 
depressive. Symptoms of depression were most prevalent among patients with a long smoking 
history, refractory dyspnoea, and a history of depression. 
Conclusion. Depression screening was positive in a third of the patients. The depression screening 
protocol improved the detection of depression symptoms, but the effects on the patients’ 
treatment and clinical course were small. Rather than referring patients to a psychiatric unit, the 
evaluation and management of depression should be undertaken at the pulmonary unit.  
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Introduction 
Depression is a common comorbidity in severe chronic pulmonary diseases. Depression diminishes 
functional performance and exercise tolerance while increasing fatigue, hospital admissions, 
morbidity and mortality (1,2). The risk for developing depression increases with the severity of 
chronic obstructive pulmonary disease (COPD) (3), and up to 30–50% of patients with severe COPD 
have depression (4,5). In patients with oxygen-dependent chronic respiratory insufficiency, the 
prevalence of depression may be as high as 60–75% (6,7).  
 
Depression is often undetected and untreated among respiratory insufficiency patients (8). 
According to previous reports, less than a third of COPD patients suffering from depression are 
being treated for it (9-11). There are several possible reasons for the low detection rate. Firstly, 
the diagnosis of depression is challenging, because the symptoms of pulmonary disease may 
resemble those of depression. In addition, both patients and health care personnel may consider 
psychiatric symptoms a normal reaction to having progressive illness rather than suspecting 
comorbid psychiatric disease (12). Finally, depression is rarely screened for in routine health care.  
 
As comorbid depression is widely undetected, routine screening for depression has been 
recommended (13,14). Nevertheless, screening should only be performed if a local depression 
treatment pathway with the possibility of consulting a psychiatrist has been established (13). Thus, 
it is essential to implement not only the screening instrument but also a care pathway allowing 
appropriate diagnostics and treatment for patients with positive screening results. However, the 
implementation of new protocols in clinical practice is usually challenging, and a variety of 
problems may arise at different organisational levels (15,16).  
 
In this paper, we describe the implementation and preliminary results of a depression screening 
protocol among respiratory insufficiency patients at a pulmonary outpatient clinic. To the best of 
our knowledge, such care pathways have not been described previously.  
Materials and Methods 
Setting 
Tampere University Hospital is a tertiary hospital situated in the southern part of Finland. It 
provides specialised care to about 530,000 people living in 23 municipalities situated within a 
110km radius from the city of Tampere. Patients with respiratory diseases are treated at the 
outpatient clinic; the annual volume is about 14,000 visits by 4,500 patients. At the outpatient 
clinic, there is a specialised section for respiratory insufficiency patients; its annual volume is 
approximately 500 patients. 
The patients are referred to the respiratory insufficiency section by physicians working in primary, 
private, or specialised health care. Typically, the patients have a severe lung, heart, or neurological 
disease with suspected chronic respiratory insufficiency. At the clinic, a pulmonologist meets the 
patient, considers the differential diagnosis, and makes decisions about medications and possible 
device treatments (long-term oxygen therapy (LTOT) and/or non-invasive ventilation (NIV)). A 
multidisciplinary team consisting of a nurse, a physiotherapist, a social worker, a dietician, and a 
rehabilitation counsellor participates in the care. Follow-up is organised according to a discrete 
protocol. 
Implementation of the depression screening protocol 
When interviewing the patients at the outpatient clinic, nurses have noticed that the patients 
often have depressive symptoms but no treatment for depression. The nurses also noted their lack 
of knowledge of how to approach such symptoms, especially as patients with chronic respiratory 
insufficiency often have difficulties in seeking help because of restricted functional ability.  
From this background, we decided to start the development and implementation of a depression 
screening protocol. The protocol was developed in collaboration with the general hospital 
psychiatric unit. For this project, a contract was drawn up to allow the referral of screening-
positive patients to the psychiatric outpatient clinic even though the usual referral criteria were 
not met. The personnel of the pulmonary unit were educated about depression detection by 
lectures and group discussions. The aim was to improve the identification of depressive 
symptoms, bring up mood symptoms in discussion, and enhance their further evaluation and 
treatment.  
The Depression Scale (DEPS) was selected as the screening instrument. The DEPS is a validated, 
self-rated screening tool for depression (17). It is the primary screening instrument for depression 
at Tampere University Hospital. The DEPS questionnaire consists of ten items, and scores vary 
from 1 to 30 points. The cut-off point for depressive symptoms is ≥9, while the cut-off point for 
clinical depression is ≥12 (18).  
Screening commenced in the autumn of 2015. Nurses were instructed to administer the DEPS 
questionnaire to every patient visiting the respiratory insufficiency section. A referral to an 
appointment at the psychiatric outpatient clinic was offered to patients with a positive screening. 
A pulmonologist made the referral, and the patient was later informed of the appointment time. 
In 2015, the cut-off for referral was ≥12/30 points. In 2016, the cut-off was lowered to ≥9/30 to 
include patients with milder symptoms. According to Sheehan and McGee (2013), a lower cut-off 
score increases the possibility of identifying depression (greater sensitivity), whereas a higher cut-
off score diminishes false-positive results (greater specificity) at the cost of sensitivity (19).  
Evaluation of screening 
Evaluation of the screening protocol was made retrospectively from the patient records. The 
patients included in the study were those who visited the respiratory insufficiency section during 
three different time periods: 17 Aug – 23 Oct 2015 (pilot phase I), 9 Nov 2015 – 15 Jan 2016 (pilot 
phase II), and 15 Sep – 31 Dec 2016 (follow-up phase).  
Patient records were reviewed to evaluate: 1) the coverage of the screening; 2) the patients’ 
willingness to fill the DEPS questionnaire; 3) the proportion of patients with positive DEPS scores; 
4) the patient characteristics associated with high DEPS scores; and 5) the consequences of 
positive screenings.  
To identify patients at an elevated risk for depression, we registered each patient’s age, gender, 
use of walking aids and home care, living arrangements, smoking history, pulmonary disease 
diagnosis, causes for chronic respiratory insufficiency, other diagnoses, use of psychoactive 
medications, available measurements of lung function (FEV1 in post-bronchodilator spirometry), 
and functional exercise capacity (6-Minute Walk test, 6MWT). In addition, the measurements 
made during the visit were gathered, including the patient’s height, weight, microspirometry, and 
the scores of the Alcohol Use Disorders Identification Test (AUDIT-C) (20), the modified Medical 
Research Council Dyspnoea Scale (mMRC) (21), and the COPD Assessment Test (CAT) (22). 
Spirometry was performed using the Vmax 20 spirometer (Sensor-Medics, Yorda Linda, CA, USA) 
and microspirometry was performed using a microspirometer (Vitalograph ® copd-6™, 
Vitalograph, Ennis, Ireland). 
Statistics 
The process of the depression screening protocol is reported descriptively. To identify patient 
groups with a high prevalence of depression symptoms, the associations of the above-mentioned 
patient characteristics with DEPS scores <9 vs ≥9 and <12 vs ≥12 were analysed. In addition, the 
results of microspirometry, spirometry, 6MWT, CAT, mMRC, and AUDIT-C were compared with the 
DEPS scores. 
Statistical significance between groups was analysed using the Mann–Whitney U test, the 
chi-squared test, or Fisher’s test as appropriate. A p-value <0.05 was considered statistically 
significant. Data management and analysis were performed using IBM SPSS Statistics 23. 
Ethics 
The implementation of depression screening in routine care was part of development work at the 
pulmonary outpatient clinic. The patients could refuse to fill the DEPS questionnaire. The 
retrospective study was organised to evaluate the outcomes of the screening, and the patients 
were not approached by the researchers. Prior to commencing the study, permission was acquired 
from the Science Centre of Tampere University Hospital. 
Results 
Baseline characteristics of the patients 
In total, 242 patients visited the respiratory insufficiency section during the defined time periods. 
Four patients using ventilators were excluded, leaving 238 for evaluation. Table 1 illustrates the 
characteristics of the included patients. Of the patients, 38 (16%) were attending their first visit, 
while the remainder had made earlier visits. A third of the patients attended a nurse’s visit only; 
the rest met both a nurse and a physician.  
Most patients had a diagnosis of chronic respiratory insufficiency (n=200, 84%), and in 75% 
(n=150) the diagnosis had been made less than five years ago. Nearly half of these patients (n=82) 
were considered to have more than one disease diagnosis as the cause for their respiratory 
insufficiency. The most common diagnoses were COPD (n=105, 53%), obstructive sleep apnoea 
(n=66, 33%), and obesity hypoventilation (n=54, 27%). Other diagnoses related to respiratory 
insufficiency were pulmonary fibrosis (n=17, 9%), pulmonary hypertension (n=17, 9%), 
neurological disorders (n=14, 7%), deformities of the chest wall (n=9, 5%), elevated 
hemidiaphragm (n=7, 4%), and miscellaneous causes (n=11, 6%). Hypertension (n=134, 56%), type 
2 diabetes (n=80, 34%), and coronary artery disease (n=46, 23%) were the most common 
comorbidities. Forty-five patients (19%) had a previous diagnosis of depression, 16 (7%) had 
another psychiatric diagnosis, and 17 (7%) had a memory disorder. Thirty-eight patients (16%) 
were using antidepressants, 88 (37%) were using anxiolytic drugs, and 23 (10%) were using 
antipsychotics. 
Outcomes of the screening 
The DEPS questionnaire was filled by 74% of the patients (n=176). The proportion of the patients 
that completed the DEPS questionnaire increased from 66% in the first year to 88% in the second 
year. Only six patients refused to fill the DEPS questionnaire. The unscreened patients were 
younger and had a lung disease diagnosis other than COPD more often compared to the screened 
patients.  
Depression screening was positive in a quarter to a third of the patients, depending on the cut-off 
point (Figure 1). Referral to psychiatric services was offered to most patients with a positive 
screening. However, more than three quarters of them declined the referral. The reasons for 
declining the referral were not systematically recorded, but there were a few notes relating to 
difficulties with travelling, and indeed, 19 of the 24 patients who declined the referral lived 
outside the city of Tampere where the psychiatric clinic is situated.  
Altogether, 13 referrals were made. Seven patients met a nurse or a psychologist at the psychiatric 
outpatient clinic. Of the remaining patients, four could not travel to the clinic; instead, they 
received a phone call to assess the severity of symptoms. Two patients died before the time of the 
appointment. All patients visiting the clinic were deemed depressive. After one or two visits, all 
patients were directed to further care at regional psychiatric services. 
Identifying the patients with a positive depression screening 
Table 2 illustrates the associations of the DEPS scores with the patients’ characteristics. High DEPS 
scores were common in patients who used walking aids or had a history of depression or heavy 
smoking. Depression screening was positive in 44% of the COPD patients, 38% of the sleep apnoea 
patients, and 29% of the obesity hypoventilation syndrome patients. Depression screening was 
positive in 43% of the patients using LTOT and 33% of the patients using NIV. Screening was 
positive in 58% of the patients with a history of depression and in 44% of the patients using 
antidepressants.  
Table 3 illustrates the associations of the DEPS scores with the measurements of lung function and 
assessment tests. The patients with high DEPS scores also had high scores in the CAT and mMRC 
tests. The FEV1 in spirometry and in microspirometry, AUDIT-C scores and distance in 6MWT were 
not associated with the DEPS scores.  
Discussion 
Symptoms of depression 
Supporting earlier observations (4,6,7), symptoms of depression were prevalent in patients: 
depression screening was positive in a third of patients. In line with earlier observations (3,9), only 
a minority had a prior diagnosis of depression or were using antidepressants, underlining the need 
for depression screening. Prior depression, a long smoking history, and the use of walking aids 
were associated with having symptoms of depression. In addition, symptomatic COPD patients 
with functional limitations owing to dyspnoea often experienced depression symptoms. Daily 
smoking has been shown to be a risk factor for depression (22), and prior depression predisposes 
to new depression (23). A relationship between CAT scores >20 and depression has been reported 
previously (24,25). Furthermore, the perception of dyspnoea is related to psychological factors, 
meaning that symptoms of depression increase dyspnoea (26). Therefore, high CAT or mMRC 
scores should be taken as sign warranting broader evaluation of the patient beyond lung 
disease-specific aims (27).  
Implementation of depression screening 
The challenges that we met when implementing the screening protocol can be divided into three 
groups based on the integrated checklist of determinants of practice (the TICD checklist) (28): 
individual health professional factors, patient factors, and professional interactions.  
Individual health professional factors include knowledge and skills, attitudes, and professional 
behaviour (28). The acceptability of the screening among nurses, measured as the proportion of 
patients who received the DEPS questionnaire, was not good in the first year of screening, but it 
improved in the second year. Nevertheless, one in ten patients went unscreened in the second 
year, although in itself, the inclusion of the DEPS questionnaire in the clinic visit appeared feasible. 
The nurses felt comfortable asking the patients to fill the DEPS questionnaire, but they 
experienced difficulties regarding how to discuss positive screening results with the patients. 
Future education of the healthcare professionals at the pulmonary clinic should therefore focus on 
communication and supportive discussion with a depressed patient. Emphasizing the importance 
of separating the symptoms of depression from those of pulmonary disease – and seeing 
improvement in both symptoms and quality of life when mood disorder is treated – would help in 
motivating for systematic, continuous use of the screening tool. 
Patient factors include beliefs and knowledge, motivation, and behaviour (28). The acceptability of 
completing the DEPS questionnaire was good, but the acceptability of referral for further 
evaluation was not: most of the screening-positive patients declined referral. This may partly be 
explained by geographical obstacles, but there are other possible explanations. Generally, COPD 
patients tend to deny depressive symptoms and usually refuse to accept referral to psychiatric 
services (12,29). The fear of stigmatisation concerning a psychiatric diagnosis may be one reason. 
Moreover, being unaware of the symptoms of depression, many patients may think that feeling 
depressed is a normal reaction to having a progressive somatic illness (8). Therefore, after a 
positive depression screening, it is important to educate patients about depression and to explain 
the potential advantages of seeking help (12). More than one discussion may be needed to 
achieve this. 
Professional interactions include communication, team processes, and referral processes (28). We 
failed to equip the professional teams with adequate skills and resources. Implementing a new 
protocol in clinical practice successfully requires changes in diverse levels of care and time for 
adjustments. In particular, the nurses at the pulmonary clinic lacked time and knowledge, and 
there were insufficient resources to have a psychiatric nurse attend the pulmonary outpatient 
clinic to interview the patients there. In addition, local care pathways for depression in 
surrounding communities were not involved in the protocol. In conclusion, the capacity for 
organisational change was not sufficient to manage patients with a positive screening. 
After the implementation of the screening, the detection of depressive symptoms certainly 
improved, but it is unclear how the screening affected the patients’ clinical course. Optimally, the 
detection and treatment of depression would improve quality of life and also reduce the 
pulmonary disease symptoms (30). Therefore, screening for depression is recommendable, but the 
issue to be resolved is how to organise services so that they are both accessible and acceptable 
from the patients’ point of view. 
In the future, greater efforts are needed to ensure that appropriate discussion is available after a 
positive screening and further evaluation of mood is more accessible for the patients. Taken 
together, one solution would be to conduct a further evaluation of mood at the pulmonary clinic 
alongside screening instead of referring patients to a psychiatric unit. For the patients, the 
pulmonary unit is a natural environment to deal with the comorbidities of the pulmonary disease. 
The fear of stigmatisation related to the diagnosis of depression would likely be lower in 
pulmonary than psychiatric unit. Furthermore, such approach would reduce the need for separate 
hospital visits that would be burdensome to the patients. The problems to be solved include 
clarifying who is competent to perform the evaluation and how the resources should be guided so 
that the patients receive a timely evaluation. However, the best solution for the patients would 
probably be a care pathway that is connected to local health care, enabling the patients to receive 
evaluation and treatment (when necessary) close to their homes. This is challenging, however, 
because practices and the availability of services concerning the suspicion of depression vary 
greatly between municipalities. 
Limitations  
This evaluation was part of developmental work at the pulmonary outpatient clinic. These data 
must be interpreted with caution because our study was a retrospective evaluation of depression 
screening outcomes. One weakness was that neither the patients nor the nurses were 
systematically interviewed for the study; thus, not all possible contributing factors were fully 
clarified. Our initial purpose was not to search for patient groups with an elevated risk for 
depression, but some risk groups were nevertheless identified in the evaluation.  
Conclusion 
Unnoticed symptoms of depression are prevalent among patients with chronic respiratory 
insufficiency. After commencing a protocol for depression screening in the pulmonary outpatient 
clinic, the detection of depression symptoms improved, but the effects on the patients’ clinical 
course were small. The patients’ compliance with the further evaluation of mood was poor. 
Screening for depression is recommendable, but the further assessment of patients with a positive 
screening should be organised in a way that is more acceptable and achievable from the patient’s 
point of view. Instead of referring patients to a psychiatric unit, the evaluation and management 
of depression should rather be performed in the pulmonary unit. 
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Table 1. Baseline characteristics of the patients. 
 n % 
Gender 
Male 
Female 
 
138 
100 
 
58 
42 
Age (years) 
<70 
70–80 
>80 
 
86 
95 
57 
 
36 
40 
24 
Place of domicile 
Tampere 
another municipality in the Pirkanmaa region 
 
95 
143 
 
40 
60 
Residence 
own home 
sheltered housing 
nursing home 
 
216 
12 
10 
 
91 
5 
4 
Home care or assistance 
none 
communal home care 
close relative as a carer  
nursing home staff 
personal assistant 
 
164 
38 
17 
10 
9 
 
69 
16 
7 
4 
4 
Use of walking aids 131 45 
Current smoking 19 8 
Smoking history in pack-years 
no smoking history 
<20 
20–40 
>40 
 
75 
31 
70 
62 
 
32 
13 
29 
26 
Use of long-term oxygen therapy or non-invasive ventilation 
long-term oxygen therapy 
portable oxygen therapy 
bilevel positive airway pressure (NIV) 
continuous positive airway pressure (CPAP) 
 
88 
75 
106 
17 
 
37 
32 
45 
7 
Body mass index (BMI) kg/m2 (n=227) 
underweight <18.5  
normal 18.5–24.9 
overweight 25–29.9 
obese ≥30 
 
12 
69 
41 
101 
 
5 
30 
18 
45 
 
 
 
 
 
Table 2. Association of the DEPS scores with the patients’ baseline characteristics in two groups 
with different cut-off points (DEPS <9 vs ≥9 and DEPS <12 vs ≥12). 
 
  
n 
DEPS ≥9  
p 
DEPS ≥12  
p % % 
Subjects 176 34   24   
Gender 
Male 
Female 
 
102 
74 
 
30  
39  
0.22  
23  
27  
0.50 
Age years 
<70  
70–80 
>80  
 
56 
79 
41 
 
43  
30  
29  
0.22 
 
 
27  
22  
27  
0.72 
Place of domicile 
Tampere 
another municipality 
 
69 
107 
 
33  
35  
0.87  
23  
25  
0.76 
Use of walking aids 
yes 
no 
 
100 
76 
 
40 
26 
0.06  
30 
17 
0.049 
Smoking history in pack-years 
No smoking history 
<20 
20–40 
>40 
 
50 
22 
55 
49 
 
28  
19  
29  
53  
0.008  
24  
9  
18  
39  
0.02 
Device treatment 
oxygen therapy 
non-invasive ventilation 
both  
none 
 
65 
70 
19 
22 
 
27 
30  
42  
18  
0.16  
31 
19  
37  
14  
0.13 
BMI† kg/m2  
underweight <18.5  
normal 18.5–24.9 
overweight 25–29.9 
obese ≥30 
 
11 
50 
39 
72 
 
18  
38  
36  
32  
0.65  
18  
30  
26  
19  
0.57 
Chronic obstructive pulmonary disease 
yes 
no 
 
103 
73 
 
39  
27  
0.12  
26  
22  
0.51 
Obstructive sleep apnoea 
yes 
no 
 
56 
120 
 
38  
33  
0.52  
27 
23  
0.62 
Obesity hypoventilation 
yes 
no 
 
35 
141 
 
29  
36  
0.44  
20  
26  
0.50 
History of depression 
yes 
no or not known 
 
31 
145 
 
58  
29  
0.002  
42  
21  
0.01 
 †BMI = Body mass index 
Table 3. The associations of DEPS scores with lung function parameters, walking test distance, and assessment tests in two groups with 
different cut-off points (DEPS <9 vs ≥9 and DEPS <12 vs ≥12). 
 
  
n 
 
All patients‡ 
DEPS  
p 
DEPS  
p <9 ≥9 <12 ≥12 
Microspirometry FEV1 
% predicted† 
litres† 
101  
40 (12─91) 
1.1 (0.4─3.0) 
 
42 (12─91) 
1.1 (0.4─3.0) 
  
39 (17─79) 
1.0 (0.4─2.5) 
 
0.65 
0.36 
 
43 (12─91) 
1.1 (0.4─3.0) 
 
36 (17─79) 
0.9 (0.4─2.1) 
 
0.16 
0.08 
Spirometry1 FEV1 
% predicted† 
litres† 
88  
55 (19─114) 
1.4 (0.4─3.6) 
 
55 (19─95) 
1.5 (0.4─3.3) 
 
52 (25–114) 
1.4 (0.7─3.6) 
1.0 
 
 
55 (19─104) 
1.5 (0.4─3.3) 
 
51 (25─114) 
1.5 (0.7─3.6) 
0.9 
 
6-Minute Walk Test (6MWT)1 
distance metres† 
96  
160 (25─500) 
 
170 (25─450) 
 
150 (35─500) 
 
0.20 
 
165 (25─480) 
 
135 (50–500) 
 
0.10 
CAT2,3,4 score† 92 22 (2─36) 19 (2─33) 25 (11─36) 0.001 19 (2─36) 25 (16–33) 0.001 
mMRC2,3,4 score† 95 3 (1─4) 3 (1─4) 3.5 (2─4) 0.001 3 (1─4) 3.5 (3─4) 0.001 
AUDIT-C5 score† 132 1 (0─12) 0 (0─10) 1 (0─12) 0.04 1 (0─10) 1 (0─12) 0.62 
†All numbers include median (range) 
‡The patients who filled the DEPS. 
1 Performed within two years prior to the visit. 
2 The COPD Assessment Test (CAT) and the modified MRC Dyspnoea Test were performed only by the COPD patients.  
3 CAT scores can range from 0 to 40. Scores >20 mean that the patient’s symptoms of lung disease have a high impact on the patient’s perceived health status. 
4 Scores on the modified MRC Dyspnoea Test can range from 0 to 4, with a score of 4 indicating that the patient is too breathless to leave the house or becomes breathless when dressing or 
undressing. 
5 AUDIT-C, the three first questions of the Alcohol Use Disorders Identification Test scores range from 0 to 12, with a score 0 indicating no alcohol use and a score >5 (among women) and >6 
(among men) indicating risky drinking that may cause health problems. 
 
 
 
